Hints and tips:
...Allergan (formerly known as Actavis and before that as Watson) describes itself as pioneering a new model in the drug sector....
...Such a transaction would continue the company’s three-year dealmaking spree, which has taken it from a run-of-the-mill generic drugmaker known as Watson Pharmaceuticals, with a market capitalisation of $8bn...
...In 2012 it was Watson Pharmaceuticals, a generic drugmaker with a market capitalisation of $8bn — a fraction of the $113bn it is worth today....
...In 2012, the group, then called Watson, was a run-of-the-mill producer of generic drugs with a market capitalisation of $8bn — a fraction of the $120bn it is worth today....
...Mr Bisaro, 53, became chief executive of what was then Watson Pharmaceuticals in 2007, when it was a run-of-the-mill generic drugs group with a market capitalisation of not much more than $3.7bn....
...Just two years ago Actavis, then known as Watson Pharmaceuticals, was a run-of-the-mill maker of generic drugs with a market capitalisation of a little over $8bn....
...It bought Watson Pharmaceuticals for $6bn (2012), Ireland-domiciled Warner Chilcott for $9bn (2013) and Forest Laboratories for $25bn (2014)....
...Mike Pearson, Valeant’s chief executive, had faced the prospect of missing out on a second big deal, after his year-long pursuit of Botox maker Allergan was thwarted by a rival $70bn bid from Actavis....
...He left in 2007 to become chief executive at Watson, the generic drug company that would later acquire Swiss-based Actavis....
...Actavis grew out of the €4.5bn reverse takeover by Watson of the US in 2012. Since then it has steadily grown by acquisition, including last year’s $8.5bn agreement to buy Ireland’s Warner Chilcott....
...Fidelity Worldwide Investment, Vanguard, Candriam, Aberdeen Asset Management, Invesco and F&C also declined to comment....
...● Watson is to rebrand next year as Actavis, the name of the Swiss-based company it bought for €4.3bn....
...The market is delighted by Watson Pharmaceuticals’ €4.5bn acquisition of Switzerland’s Actavis....
...Actavis has about 300 projects in its development pipeline and manufactured more than 22bn pharmaceutical doses in 2011....
...The FTSE 100 drugmaker’s shares fell as much as 13 per cent after the FDA granted approval for Watson Pharmaceuticals’ Actavis unit to produce a cut-price version of Adderall XR, one of Shire’s top-selling...
...Generic drug companies have been looking for greater scale lately, highlighted by Watson’s acquisition of Actavis for €4.5bn in April and Teva’s $6.8bn acquisition of Cephalon last year....
...Watson Pharmaceuticals, the US generic drugmaker, is in talks to acquire Actavis in a deal that could value it Swiss rival at around €4.5bn, according to people familiar with the matter....
...Last week Watson Pharmaceuticals acquired Actavis in a $5.6bn deal, positioning the combined company as the third largest generics maker by sales....
...A Reuters report said the company was in talks to buy Actavis Group, a Switzerland-based generic drugmaker, for up to €5.5bn. Shares in Watson gained 8.8 per cent to $63.69....
...Frances Cloud, a consultant to the generics industry, warns that innovative pharmaceutical groups recent inroads will be shortlived, given the modest scale and lower margins of the niche....
...“There are a number of actions coming,” says Paul Bisaro, head of Watson, the US generic medicines company. “The probes are causing a lot of people to sit up and take notice.”...
...F....
International Edition